Resveratrol demonstrates anticancer activity across nine distinct cancer types—including breast, prostate, colon, and brain cancers—by triggering cell cycle arrest, activating apoptosis, and suppressing metastasis through multiple signaling pathways. The stilbene compound, concentrated in grapes and berries, extends lifespan in animal cancer models while reducing tumor development. This polyphenolic mechanism represents a particularly compelling approach to cancer intervention because it targets fundamental cellular processes that malignant cells exploit. Unlike single-target therapies that cancer cells often develop resistance to, resveratrol's multi-pathway interference may offer more durable therapeutic benefits. The compound's natural origin and demonstrated safety profile in dietary consumption adds practical appeal for both prevention and adjuvant therapy applications. However, significant translation challenges remain. Most promising results come from animal studies, and human bioavailability of resveratrol is notoriously poor due to rapid metabolism. The review's narrative format also limits systematic assessment of effect sizes across studies. While the breadth of anticancer activity is impressive, the field needs rigorous dose-response studies and enhanced delivery mechanisms before resveratrol can fulfill its therapeutic promise in clinical oncology.